India · Delayed Price · Currency is INR Strides Pharma Science Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw record EBITDA and PAT, driven by ex-U.S. market growth and margin expansion. U.S. business faced headwinds from a weak flu season and competition, but new launches and controlled substances are expected to drive growth from H2 FY 2027.
-
Gross margins and profitability improved, with EBITDA and PAT showing strong year-on-year growth. Ex-U.S. markets drove revenue expansion, while U.S. business remained flat due to seasonal and competitive factors. Balance sheet metrics and operational cash flow strengthened.
-
Q2 and H1 FY26 delivered strong growth in revenue, margins, and profitability, driven by disciplined execution, operating leverage, and a focus on sustainable, long-term growth. U.S. and other regulated markets showed steady performance, with robust cash flow and debt reduction.
-
Strong quarterly results with revenue of INR 11.2 billion, 19.5% EBITDA margin, and 81% EPS growth year-on-year. U.S. and growth markets performed well, while access markets faced funding challenges. Long-term U.S. sales guidance of $400 million by FY2028 remains intact.
Fiscal Year 2025
-
FY25 delivered strong revenue and EBITDA growth, surpassing guidance across all key metrics, with the US business leading at 22% growth. The company achieved significant deleveraging, maintained high margins, and is increasing R&D investment for future growth, targeting sustained high-teens EBITDA margins.
-
Strong Q3 and nine-month results driven by robust US and emerging market growth, margin expansion, and successful soft-gelatin business demerger. Debt reduction and improved cash cycle position the company to meet FY25 guidance and long-term growth targets.
-
Strong quarterly and H1 results with 17% revenue growth, record EBITDA, and improved margins. U.S. and CDMO segments led performance, with guidance raised to the higher end and robust outlook for GLP-1 and softgel businesses. Net debt and ROCE improved significantly.
-
Q1 FY25 saw record revenue and profitability, with U.S. sales up 34.5% and EBITDA margin at 20%. Debt reduction, strong cash flow, and improved credit outlook support confidence in meeting FY25 guidance.